CRVO CervoMed Inc.
CervoMed Inc. (CRVO) is expected to report earnings on November 6, 2026, before the market open. The consensus earnings estimate is a loss of $0.53 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -3.9% since its last earnings release on August 7, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About CervoMed Inc.
CervoMed Inc. is a clinical-stage biotechnology company advancing CNS-focused therapeutics for patients with a range of degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant which inhibits p38MAP kinase alpha. CervoMed Inc., formerly known as Diffusion Pharmaceuticals Inc., is based in BOSTON.
Sector
Healthcare
Industry
Biotechnology